Filing Flows › Comparisons › RXRX vs DNLI
Recursion Pharmaceuticals vs Denali Therapeutics: RXRX and DNLI compared
Recursion Pharmaceuticals is the larger company: $18.6M of revenue in its latest quarter (Q3 2026) against $17.8M for Denali Therapeutics (Q3 2026). Recursion Pharmaceuticals is more profitable, with an operating margin of -663.9% against -713.0%.
Where the money goes: RXRX and DNLI
Recursion Pharmaceuticals (RXRX) · Q3 2026
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Denali Therapeutics (DNLI) · Q3 2026
Denali Therapeutics, Q3 2026: revenue $17.8M, operating margin -713.0%, net earnings $70.1M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.
| Recursion Pharmaceuticals (RXRX) | Denali Therapeutics (DNLI) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $18.6M | $17.8M |
| Revenue growth, Y/Y | +258% | — |
| Operating margin | -663.9% | -713.0% |
| Net earnings | −$119M | $70.1M |
| Net margin | -641.6% | 394.5% |
| Operating cash flow | −$77.4M | −$117M |
Where the revenue comes from
Recursion Pharmaceuticals
- Operating revenue: $18.1M (97%)
- Grant revenue: $497K (3%)
Questions
Which is bigger, Recursion Pharmaceuticals or Denali Therapeutics?
Recursion Pharmaceuticals is the larger company: $18.6M of revenue in its latest quarter (Q3 2026) against $17.8M for Denali Therapeutics (Q3 2026).
Is Recursion Pharmaceuticals or Denali Therapeutics growing faster?
Recursion Pharmaceuticals is more profitable, with an operating margin of -663.9% against -713.0%.
More: Recursion Pharmaceuticals earnings · how Recursion Pharmaceuticals makes money · Denali Therapeutics earnings · how Denali Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.